Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index; none of the 28 sources its claims cite is checked for support yet.

Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder

Open access
Iosifescu, Dan V., Jones, Amanda, O’Gorman, Cedric, Streicher, Caroline, Feliz, Samantha, Fava, Maurizio, Tabuteau, Herriot·2022·The Journal of Clinical Psychiatry

Abstract

Objective: Altered glutamatergic neurotransmission has been implicated in the pathogenesis of depression. This trial evaluated the efficacy and safety of AXS-05 (dextromethorphan-bupropion), an oral N-methyl-D-aspartate (NMDA) receptor antagonist and σ1 receptor agonist, in the treatment of major depressive disorder (MDD). Methods: This double-blind, phase 3 trial, was conducted between June 2019 and December 2019. Patients with a DSM-5 diagnosis of MDD were randomized in a 1:1 ratio to receive dextromethorphan-bupropion (45 mg-105 mg tablet) or placebo, orally (once daily for days 1–3, twice daily thereafter) for 6 weeks. The primary endpoint was the change from baseline to week 6 in the Montgomery-Asberg Depression Rating Scale (MADRS) total score. Other efficacy endpoints and variables included MADRS changes from baseline at week 1 and 2, clinical remission (MADRS score ≤ 10), clinical response (≥ 50% reduction in MADRS score from baseline), clinician- and patient-rated global assessments, Quick Inventory of Depressive Symptomatology-Self-Rated, Sheehan Disability Scale, and quality of life measures. Results: A total of 327 patients were randomized: 163 patients to dextromethorphan-bupropion and 164 patients to placebo. Mean baseline MADRS total scores were 33.6 and 33.2 in the dextromethorphan-bupropion and placebo groups, respectively. The least-squares mean change from baseline to week 6 in MADRS total score was −15.9 points in the dextromethorphan-bupropion group and −12.0 points in the placebo group (least-squares mean difference, −3.87; 95% confidence interval , −1.39 to −6.36; P = .002). Dextromethorphan-bupropion was superior to placebo for MADRS improvement at all time points including week 1 (P = .007) and week 2 (P < .001). Remission was achieved by 39.5% of patients with dextromethorphan-bupropion versus 17.3% with placebo (treatment difference, 22.2; 95% CI, 11.7 to 32.7; P < .001), and clinical response by 54.0% versus 34.0%, respectively (treatment difference, 20.0%; 95% CI, 8.4%, 31.6%; P < .001), at week 6. Results for most secondary endpoints were significantly better with dextromethorphan-bupropion than with placebo at almost all time points (eg, CGI-S least-squares mean difference at week 6, −0.48; 95% CI, −0.48 to −0.79; P = .002). The most common adverse events in the dextromethorphan-bupropion group were dizziness, nausea, headache, somnolence, and dry mouth. Dextromethorphan-bupropion was not associated with psychotomimetic effects, weight gain, or increased sexual dysfunction. Conclusions: In this phase 3 trial in patients with MDD, treatment with dextromethorphan-bupropion (AXS-05) resulted in significant improvements in depressive symptoms compared to placebo starting 1 week after treatment initiation and was generally well tolerated. Trial Registration: ClinicalTrials.gov Identifier: NCT04019704

Overview

CoChat Summary

TL;DR

In this phase 3 randomized trial, AXS-05 (dextromethorphan-bupropion) produced significantly greater reduction in MADRS total score than placebo at week 6 in patients with major depressive disorder, with separation from placebo by week 1. AXS-05 was generally well tolerated, with dizziness, nausea, headache, somnolence, and dry mouth as the most common adverse events.

Key findings

  • Primary endpoint: least-squares mean change from baseline to week 6 in MADRS total score was −15.9 points with dextromethorphan-bupropion vs −12.0 with placebo (least-squares mean difference, −3.87; 95% CI, −1.39 to −6.36; P = .002).
  • Early efficacy: MADRS change at week 1 was −7.20 vs −4.97 (difference, −2.23; 95% CI, −0.60 to −3.86; P = .007), and at week 2 was −11.09 vs −7.66 (difference, −3.44; 95% CI, −1.40 to −5.47; P < .001).
  • At week 6, remission (MADRS ≤ 10) was 39.5% vs 17.3% (treatment difference, 22.2%; 95% CI, 11.7%–32.7%; P < .001), and clinical response (≥ 50% MADRS reduction) was 54.0% vs 34.0% (treatment difference, 20.0%; 95% CI, 8.4%–31.6%; P < .001).
  • Safety: adverse events occurred in 61.7% vs 45.1%; adverse events leading to discontinuation occurred in 6.2% vs 0.6%. Dextromethorphan-bupropion was not associated with psychotomimetic effects, weight gain, or increased sexual dysfunction, and there were no suicide-related adverse events or suicidal behaviors on the C-SSRS.

Methods

  • Phase 3, randomized, double-blind, placebo-controlled, 6-week trial conducted at 40 US centers from June 2019 to December 2019; 327 patients were randomized 1:1 to dextromethorphan-bupropion 45 mg–105 mg or placebo (once daily for days 1–3, twice daily thereafter). The modified intent-to-treat population included 156 patients in the dextromethorphan-bupropion group and 162 in the placebo group.
  • Patients were men or women aged 18–65 years with DSM-5 MDD, a major depressive episode of at least 4 weeks, MADRS total score ≥ 25, and CGI-S score ≥ 4. Key exclusions included bipolar disorder, psychotic disorder, panic disorder, obsessive-compulsive disorder, treatment-resistant depression, alcohol/substance use disorder within the past year, clinically significant suicide risk, and seizure disorder history.
  • The primary endpoint was change from baseline to week 6 in MADRS total score, analyzed using a mixed model for repeated measures/ANCOVA with treatment, week, treatment-by-week interaction, baseline value as covariate, and patient as random effect. Percentage endpoints were analyzed via χ² tests; key secondary endpoints used hierarchical testing; no imputation was used for primary or secondary endpoints, with sensitivity analyses by random replacement and tipping point methods.

Limitations

  • Stated in the paper: exclusions of patients with psychotic or other psychiatric disorders, alcohol/substance use disorders, clinically significant suicide risk, or significant medical comorbidities may limit generalizability; treatment at experienced trial sites by specialized clinicians under a protocol with frequent assessments may not reflect general practice; dropout was 24.1% in the dextromethorphan-bupropion group vs 10.4% with placebo; multiplicity adjustments were applied only to key secondary endpoints; and trial duration was limited to 6 weeks.
  • Evident from the text: the sponsor designed the protocol, oversaw study conduct, analyzed and interpreted data, authored the manuscript, and had final decision to submit it; baseline sex distribution differed between groups (39.1% male with dextromethorphan-bupropion vs 27.8% with placebo; P = .033).

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.4088/jcp.21m14345

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

0 Valid · 0 Not valid · 18 Not checked · 70 Own results and interpretations

45 more claims

Create a free account to see all 88 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 23
  • It may state two separate claims as one. 22

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

8 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 23 references

Research works printed but not linked: 10

  1. P u M e d C r o s s R e f 4. Machado-Vieira R, Henter ID, Zarate CA Jr. New targets for rapid antidepressant action. Prog Neurobiol. 2017;152:21-37. · DOI · Paper page
  2. P u b M e d C r o s s R e f 10. Fava M, Freeman MP, Flynn M, et al. Double- blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2020;25(7):1592-1603. · DOI · Paper page
  3. P u b M e d C r o s s R e f 12. Nguyen L, Robson MJ, Healy JR, et al. Involvement of sigma-1 receptors in the antidepressant-like effects of dextromethorphan. PLoS One. 2014;9(2):e89985. P u b M e d C r o s s R e f 13. Niciu MJ, Ionescu DF, Richards EM, et al. Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder. J Neural Transm (Vienna). 2014;121(8):907-924. · DOI · Paper page
  4. P u b M e d C r o s s R e f 22. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573-583. · DOI
  5. P u b M e d C r o s s R e f 26. Bech P. Rating scales in depression: limitations and pitfalls. Dialogues Clin Neurosci. 2006;8(2):207-215. · DOI
  6. P u M e d C r o s s R e f 28. Khan A, Bhat A, Kolts R, et al. Why has the antidepressant-placebo difference in antidepressant clinical trials diminished over the past three decades? CNS Neurosci Ther. 2010;16(4):217-226. · DOI · Paper page
  7. P u b M e d C r o s s R e f 29. Keefe RS, Kraemer HC, Epstein RS, et al. Defining a clinically meaningful effect for the design and interpretation of randomized controlled trials. Innov Clin Neurosci. 2013;10(suppl A):4S-19S. P u b M e d 30. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-1917. · DOI · Paper page
  8. P u b M e d C r o s s R e f 31. Cheung CP, Thiyagarajah MT, Abraha HY, et al. The association between placebo arm inclusion and adverse event rates in antidepressant randomized controlled trials: an examination of the Nocebo Effect. J Affect Disord. 2021;280(Pt A):140-147. · DOI · Paper page
  9. P u b M e d C r o s s R e f 32. Schalkwijk S, Undurraga J, Tondo L, et al. Declining efficacy in controlled trials of antidepressants: effects of placebo dropout. Int J Neuropsychopharmacol. 2014;17(8):1343-1352. · DOI
  10. P u M e d C r o s s R e f · DOI · Paper page

Cited by

See all 135

Metadata

Authors
Iosifescu, D. V., Jones, A., O’Gorman, C., Streicher, C., Feliz, S., Fava, M., & Tabuteau, H.
Affiliations
Axsome Therapeutics (United States) (US)
Corresponding author
Jones, Amanda
Venue
The Journal of Clinical Psychiatry
Published
2022-05-30
Volume
83
Issue
4
ISSN
  • 0160-6689 (ISSN-L)
  • 1555-2101
OpenAlex
W4281570368
Cited by
135
References
23
Citations by year
2026: 27 · 2025: 36 · 2024: 34 · 2023: 31 · 2022: 7
FWCI
16.16
Type
journal article
Language
en
Open access
Locations
  • The Journal of Clinical Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (acceptedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacological Receptor Mechanisms and Effects
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords
major depressive disorder, NMDA receptor antagonists, sigma-1 receptor agonist, glutamatergic neurotransmission, antidepressant efficacy, antidepressant safety, clinical remission, quality of life, disability, adverse events, drug tolerability, rapid antidepressant response
MeSH terms
Major Depressive Disorder, Dextromethorphan, Double-Blind Method, Humans, Quality of Life, Bupropion

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder. https://app.cochat.ai/papers/10.4088/jcp.21m14345
The paper
Iosifescu, D. V., Jones, A., O’Gorman, C., Streicher, C., Feliz, S., Fava, M., & Tabuteau, H. (2022). Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.21m14345

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.